DexCom, Inc. (NASDAQ: DXCM) declared Wednesday that it has concluded the distribution deal with Zkope Healthcare. The firm has disclosed that it has also commenced the selling of the Dexcom G6 CGM system directly throughout the Netherlands.
The firm is striving to increase the reach of CGM for people with diabetes all around the globe. DXCM disclosed that it has decided to commence direct selling because it will benefit the firm by providing direct market access. Through its direct access, it will be able to bring CGM technology to sufferers and healthcare suppliers across the Netherlands.
DexCom G6 utilizes a small, easy-to-carry sensor and transmitter to constantly evaluate and transmit glucose levels through a wireless connection to a receiver or compatible smart device. The greatest benefit of CGM will help individuals with diabetes to get real-time glucose data without the necessity of imaging or to pierce their fingers.
The G6 app for well-suited iOS and Android devices also allows users to share their glucose data with up to five followers. It also allows family, loved ones to share their medical history with healthcare suppliers to vaguely monitor them for extra peace of mind. The Dexcom G6 CGM system is specified in the Netherlands for sufferers with diabetes two years of age and older, including women who are pregnant.
Benefits of Dexcom G6 CGM
DexCom G6 CGM provides various benefits to the sufferers. It eliminates the fingersticks or searching for measurement. Sufferers will also be able to automatically send every five minutes via Bluetooth to any compatible smart device or a Dexcom receiver. Furthermore, it is a newly devised receiver with a touchscreen display.